Featured Research

from universities, journals, and other organizations

New Class Of Protease Inhibitors May Be Effective In Treating One Of Latin America's Most Devastating Diseases

Date:
August 20, 1998
Source:
University Of California, San Francisco
Summary:
Researchers at the San Francisco Veterans Affairs Medical Center and UC San Francisco have demonstrated that a type of drug known as a cysteine protease inhibitor may be highly effective against American trypanosomiasis or Chagas1 disease, which is caused by an infection with the parasite Trypansoma cruzi (T. cruzi).

SAN FRANCISCO, Calif.--Researchers at the San Francisco Veterans Affairs Medical Center and UC San Francisco have demonstrated that a type of drug known as a cysteine protease inhibitor may be highly effective against American trypanosomiasis or Chagas1 disease, which is caused by an infection with the parasite Trypansoma cruzi (T. cruzi).

Chagas is the leading cause of heart disease in Latin America and approximately 50,000 people die every year as a result of it. Once confined to Latin America, cases of Chagas1 disease have been reported in the United States. The study provides proof that this new class of protease inhibitors can be safely used in animals to treat a parasitic infection, the researchers said.

The study, published in the August 17 issue of the Journal of Experimental Medicine, reports on the treatment of 21 mice infected with lethal doses of T. cruzi. All of the treated mice were rescued from the infection. A control group of untreated mice all died within four to ten days. Some of the treated mice were followed for as long as a year with no evidence of disease or parasites.

Importantly, the cysteine protease inhibitors produced no side-effects in the animals, and there was no indication of drug resistance. According to senior author James H. McKerrow, MD, PhD, director of the National Institutes of Health-sponsored Tropical Disease Research Unit at the San Francisco VA Medical Center, and UCSF professor of pathology and pharmaceutical chemistry, the study demonstrates in mice that cysteine protease inhibitors stop T. cruzi from replicating by 3turning off2 a specific enzyme critical to the parasite1s survival -- much like aspartate protease inhibitors work against Human Immunodeficiency Virus (HIV).

Because cysteine and aspartate protease inhibitors function in similar ways, the researchers are optimistic about the drug1s safety and efficacy in humans.

While its potential as a Chagas treatment is very encouraging, perhaps equally important is that we have provided proof of the concept that cysteine protease inhibitors can stop a parasite from replicating without harming the host cell,2 says McKerrow. This proof of the concept could pave the way for new treatments for other kinds of infections, and perhaps for diseases such as cancer and arthritis which also involve the action of cysteine proteases, he says.

Chagas1 disease affects an estimated 16-18 million people throughout Latin America and approximately 90 million more are at risk. It is spread by the bite of certain blood-sucking insects and through transfusions with infected blood products.

At present the only therapies for Chagas1 disease are highly toxic and treatment must be carefully monitored by medical personnel. The current medications only cure about 60 percent of infections and, worse yet, in some geographical regions T. cruzi appears to be resistant to the commonly used medications.

T. cruzi primarily invades heart muscle and certain nerves, slowly destroying cells. When the parasite attacks the human heart, most victims become acutely ill for four to six weeks but then enter a chronic phase with few or no symptoms. However, during this quiet period, which can last for decades, T. cruzi continues to multiply and weaken the heart. As a result, the victim is slowly crippled and eventually dies as a result of heart failure.

Before cysteine protease inhibitors can be distributed for human use, they still must pass additional toxicology and safety studies which are currently underway. According to McKerrow, the preliminary results are promising. If approved by the Food and Drug Administration (FDA), McKerrow says the drug should be relatively inexpensive.

Co-investigators of the SFVAMC-UCSF study were Juan C. Engel, PhD, associate research parasitologist; Patricia S. Doyle, PhD, assistant research parasitologist; and Ivy Hsieh, MA, staff research associate; all of the UCSF Department of Pathology.

The study was funded with grants from the National Institutes of Health and the American Heart Association.


Story Source:

The above story is based on materials provided by University Of California, San Francisco. Note: Materials may be edited for content and length.


Cite This Page:

University Of California, San Francisco. "New Class Of Protease Inhibitors May Be Effective In Treating One Of Latin America's Most Devastating Diseases." ScienceDaily. ScienceDaily, 20 August 1998. <www.sciencedaily.com/releases/1998/08/980820075704.htm>.
University Of California, San Francisco. (1998, August 20). New Class Of Protease Inhibitors May Be Effective In Treating One Of Latin America's Most Devastating Diseases. ScienceDaily. Retrieved July 30, 2014 from www.sciencedaily.com/releases/1998/08/980820075704.htm
University Of California, San Francisco. "New Class Of Protease Inhibitors May Be Effective In Treating One Of Latin America's Most Devastating Diseases." ScienceDaily. www.sciencedaily.com/releases/1998/08/980820075704.htm (accessed July 30, 2014).

Share This




More Health & Medicine News

Wednesday, July 30, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Health Insurers' Profits Slide

Health Insurers' Profits Slide

Reuters - Business Video Online (July 30, 2014) Obamacare-related costs were said to be behind the profit plunge at Wellpoint and Humana, but Wellpoint sees the new exchanges boosting its earnings for the full year. Fred Katayama reports. Video provided by Reuters
Powered by NewsLook.com
Concern Grows Over Worsening Ebola Crisis

Concern Grows Over Worsening Ebola Crisis

AFP (July 30, 2014) Pan-African airline ASKY has suspended all flights to and from the capitals of Liberia and Sierra Leone amid the worsening Ebola health crisis, which has so far caused 672 deaths in Guinea, Liberia and Sierra Leone. Duration: 00:43 Video provided by AFP
Powered by NewsLook.com
At Least 20 Chikungunya Cases in New Jersey

At Least 20 Chikungunya Cases in New Jersey

AP (July 30, 2014) At least 20 New Jersey residents have tested positive for chikungunya, a mosquito-borne virus that has spread through the Caribbean. (July 30) Video provided by AP
Powered by NewsLook.com
Generics Eat Into Pfizer's Sales

Generics Eat Into Pfizer's Sales

Reuters - Business Video Online (July 29, 2014) Pfizer, the world's largest drug maker, cut full-year revenue forecasts because generics could cut into sales of its anti-arthritis drug, Celebrex. Fred Katayama reports. Video provided by Reuters
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins